Prader-Willi Syndrome (PWS) – Epidemiology Insights and Forecast Report – 2020 To 2040

Prader-Willi Syndrome (PWS) Epidemiology Insights

Thelansis’s “⁠Prader-Willi Syndrome (PWS) Epidemiology Insights and Forecast Report – 2020 To 2040″ provides an analysis of disease burden, characterized by disease definition, prevalence, incidence, diagnosed cases, severity, comorbidities, and clinical manifestations. Potential patient flow dynamics in disease burden are driven by shifts in demographic indicators and their correlation with age and gender distribution over time. Changes in the reported cases and long-term survival of patients may depend on diet, lifestyle, comorbid conditions, and the availability of interventions or therapies.

Prader-Willi Syndrome (PWS) Overview

Prader-Willi syndrome (PWS) is a complex, multisystem neurodevelopmental and endocrine disorder fundamentally caused by the loss of function of imprinted genes on the paternally inherited chromosome 15 (15q11.2-q13), most commonly resulting from a paternal microdeletion or maternal uniparental disomy. The disease is clinically characterized by a highly distinct, biphasic developmental and nutritional trajectory. In the neonatal period, patients present with profound central hypotonia, poor suck reflex, and failure to thrive; however, during early childhood, this relentlessly transitions into severe hyperphagia—an insatiable, biologically driven hunger resulting from profound hypothalamic dysfunction. If left unchecked, this lack of satiety rapidly precipitates morbid obesity and catastrophic metabolic comorbidities, including type 2 diabetes and severe obstructive sleep apnea. The phenotypic spectrum is further complicated by characteristic behavioral and psychiatric challenges, mild-to-moderate intellectual disability, and multiple endocrinopathies, most notably hypogonadism and central growth hormone deficiency. The modern standard of care mandates rigorous, multidisciplinary intervention. While the early initiation of recombinant human growth hormone (rhGH) therapy is the established standard for significantly improving linear growth, body composition, and metabolic homeostasis, there are currently no approved pharmacological therapies to mitigate the underlying hyperphagia. Consequently, long-term survival and management continue to rely heavily on strict, lifelong environmental security—including locked access to food—and relentless caregiver supervision.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Deliverables format and updates*:

• Access to an interactive epidemiology platform with downloadable Excel and PPT files.
• Global findings
• G8 findings
• Regional findings
• Country-specific findings
• Others*: regular updates, customizations, epidemiologist support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the content. Countries, subpopulations, and years of forecast can be customized as per client requirements.

Key business questions answered:

• 20-year historical and forecast data (2020–2040)
• Disease definition based on globally accepted and latest criteria (e.g., ICD-10 codes)
• Granular patient population coverage by year and geography
• Detailed segmentation by age, gender, subpopulations, comorbidities, line of therapies, etc.
• Patient funnels
• Country comparisons
• Relevant clinical variables (e.g., staging/classification/severity)

Insights driven by robust research and estimates:

• Published literature (e.g., peer-reviewed journal articles, registries, national surveys)
• Primary market research with KOLs
• RWD analysis using claims and EHR datasets
• Proprietary mathematical models (e.g., incidence-survival model; incidence- recurrence/progression-survival model)

Read more: Prader-Willi Syndrome (PWS) – Epidemiology Insights and Forecast Report – 2020 To 2040